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Introduction: We investigated safety, efficacy, and recurrence after 
postoperative hemithoracic intensity-modulated radiation therapy 
(IMRT) in patients with malignant pleural mesothelioma treated 
with extrapleural pneumonectomy (EPP), during the past decade at 
a single institution.
Methods: In 2001–2011, 136 consecutive patients with malignant 
pleural mesothelioma underwent EPP with planned adjuvant IMRT. 
Eighty-six patients (64%) underwent hemithoracic IMRT; the rest 
were not eligible because of postoperative complications, disease 
progression, or poor performance status. We assessed toxicity, sur-
vival, and patterns of failure in these 86 patients. Toxicity was scored 
with the Common Terminology Criteria for Adverse Events ver-
sion 4.0; survival outcomes were estimated with the Kaplan–Meier 
method; and locoregional patterns of failure were classified as in-
field, marginal, or out-of-field. Risk factors related to survival were 
identified by univariate and multivariate Cox regression analysis.
Results: Median overall survival time for all 86 patients receiving 
IMRT was 14.7 months. Toxicity rates of grade of 3 or more were: skin 
17%, lung 12%, heart 2.3%, and gastrointestinal toxicity 16%. Five 
patients experienced grade 5 pulmonary toxicity. Rates of locoregional 
recurrence-free survival, distant metastasis-free survival, and overall 
survival (OS) were 88%, 55%, and 55% at 1 year and 71%, 40%, and 
32% at 2 years. On multivariate analysis, pretreatment forced expira-
tory volume in 1 second, nonepithelioid histology, and nodal status 
were associated with distant metastasis-free survival and OS.
Conclusion: IMRT after EPP is associated with low rates of locore-
gional recurrence, though some patients experience life-threatening 
lung toxicity. Tumor histology and nodal status can be helpful in 
identifying patients for this aggressive treatment.
Key Words: Malignant pleural mesothelioma, Extrapleural Pneumo-
nectomy, Intensity-modulated radiotherapy.
(J Thorac Oncol. 2013;8: 238–245)
Malignant pleural mesothelioma (MPM) is a rare and deadly cancer that primarily occurs decades after expo-
sure to asbestos. Outcomes have remained dismal despite 
aggressive treatment strategies. Extrapleural pneumonec-
tomy (EPP) is an aggressive and increasingly controversial 
approach1 that can be used to surgically treat this malignancy, 
although patients remain at high risk for locoregional failure 
and nearly all die of the disease even after EPP.2 Hemithoracic 
radiation therapy has been used to control microscopic resid-
ual disease and minimize the risk of locoregional recurrence 
(LR). Although the initial reports of this approach involved 
conventional three-dimensional conformal radiation ther-
apy,3,4 subsequent studies suggest that postoperative radiation 
is feasible when delivered as intensity-modulated radiation 
therapy (IMRT), with promising rates of locoregional con-
trol.5 However, results of this technique from large databases6,7 
other than the Surveillance, Epidemiology, and End Results 
database are limited.8
The purpose of this study was to summarize our experi-
ence with this strategy at a high-volume tertiary cancer care 
center over the past decade, focusing on toxicity and sur-
vival outcomes. We also analyzed patterns of failure of this 
combined-modality technique to estimate the percentage of 
patients who experience recurrences at the radiation margin 
and to determine whether the radiation fields currently being 
used for this purpose are appropriate.
PATIENTS AND METHODS
Eligibility
This retrospective study was approved by the Institutional 
Review Board of The University of Texas M.D. Anderson 
Cancer Center. We identified 136 consecutive patients who 
had undergone EPP for MPM at M.D. Anderson Cancer 
Center between January 2001 and April 2011. Eighty-six of 
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these patients (64%) ultimately underwent hemithoracic IMRT 
and their characteristics are listed in Table 1. We routinely 
recommend hemithoracic IMRT after EPP when patients 
recover from surgery, typically within 2 to 3 months, if the 
patient can tolerate it. Of the 50 patients who did not undergo 
IMRT after EPP in this study, 22 were not treated because 
of poor performance status after surgery; 11 died before they 
could be considered for radiation (6 from pneumonia or acute 
respiratory distress syndrome, 1 from pulmonary embolism, 
1 from bronchopleural fistula, 1 from intraoperative bleeding 
followed by cardiac arrest, and 2 from cardiac arrest of 
unknown causes); 12 patients were not considered candidates 
for radiation because of distant metastasis (DM) or significant 
local recurrence (LR) found at or before computed tomography 
(CT) treatment simulation; and five refused radiation or were 
lost to follow-up. Chemotherapy regimens included cisplatin/
pemetrexed (n = 25), cisplatin alone (n = 4), cisplatin/
gemcitabine (n = 3), carboplatin/pemetrexed (n = 2), and 
dasatinib+/−systemic therapy (n = 8).
It is evident from examining Table 1 that there are no sig-
nificant differences in the majority of variables between those 
patients who received IMRT versus those who did not, includ-
ing performance status at the time of diagnosis, stage, and 
histology, further highlighting the intention to treat approach 
that is taken in all patients who receive an EPP. Indeed, not 
one patient who underwent EPP alone received adjuvant che-
motherapy, which supports the premise that this subgroup of 
patients was not eligible for any adjuvant therapy.
Surgery
All patients underwent staging studies, including posi-
tron emission tomography or CT, bronchoscopy, laparoscopy, 
and mediastinoscopy before surgery to identify transdia-
phragmatic extension and contralateral hemithoracic disease; 
none had evidence of DM before EPP. Pulmonary and renal 
function was evaluated with spirometry, quantitative ven-
tilation/perfusion scanning, and radioisotope renography. 
The surgical procedure involved an en bloc resection of the 
lung, parietal pleura, visceral pleura, ipsilateral pericardium, 
and diaphragm, with reconstruction of the pericardium and 
diaphragm with polytetrafluoroethylene, as described previ-
ously.9 Complications of surgical resection are depicted in 
Table 2.
Radiation Therapy
All patients underwent four-dimensional CT-based 
treatment simulation before radiation therapy. Simulation 
took place while the patients were supine and immobilized 
in an upper body cradle, with both arms overhead, grasping 
a T-bar. A bolus, 3.0-3.5 cm circumference, was placed over 
the incision and drainage sites. The ipsilateral hemithorax was 
contoured as the clinical target volume, which included the 
pleural space, scars, drain sites, and involved nodal stations. 
These contours were drawn in consultation with the operating 
surgeon to identify specific regions that required a boost. This 
volume was then expanded to include a margin for internal 
motion, and an additional 0.5- to 1.0-cm margin was added to 
account for patient movement (the planning target volume). 
TABLE 1.  Patient Characteristics in EPP+IMRT Group  
(n = 86) and EPP Alone (n = 50)
Characteristic EPP+IMRT n (%) EPP Alone n (%) p
Age at EPP, yr
 Median 59.8 62.5
 Mean 60.6 61.9 0.132
 Range 37.4–77.9 41.3–77.6
Sex
 Male 76 40
 Female 10 10 0.214
Side
 Right 57 29
 Left 29 21
0.361
ECOG PS score at diagnosis
 0 35 14
 1 44 31 0.137
 2 7 3
 3 0 2
Pretreatment FEV1  
predicted value %
Median 70 69
Mean 73 72 0.78
Range 40–109 50–110
Pretreatment DLCO  
predicted value %
Median 80 75 0.247
Mean 81 76
Range 23–121 46–110
T status
 T2 9 7
 T3 71 36 0.3
 T4 6 7
N stage
 N0 44 24
 N1 15 5 0.319
 N2 27 21
Tumor histology
 Epithelioid 66 32 0.333
 Sarcomatoid/Biphasic 
Interval Between Surgery 
and Radiation (mo)
23 18
 Median 2.4 —
 Mean 2.6 (—)
 Range 1.3–7.0
Mean lung dose, Gy
 Median 6.61
 Mean 6.74 —
 Range 4.28–8.7 (—)
Mean esophageal dose, Gy
 Median 35.3
 Mean 35.4 —
 Range 26.0–44.9 (—)
Chemotherapy
 None 57 38
 Induction 20 12 0.051
 Adjuvant 12 0
EPP, extrapleural pneumonectomy; ECOG PS, Eastern Cooperative Oncology 
Group performance status; FEV1, forced expiratory volume in 1 second; DLCO, carbon 
monoxide lung diffusion capacity; AJCC, American Joint Committee on Cancer; IMRT, 
intensity-modulated radiation therapy.
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Details of our radiation treatment planning approach have 
been published elsewhere.10
The dose prescribed to the planning target volume was 
45 to 50 Gy in 25 daily fractions. Thirteen patients received 
a radiation boost of 55 to 60 Gy in areas identified by the 
surgeon as being at high risk for residual disease or as posi-
tive margins. Standard dose constraints in the remaining lung 
included a mean lung dose less than 8.0 Gy; the esophagus 
(V
50
) received less than 50%, and the mean dose to the esopha-
gus was less than 34 Gy. Mean dose to the heart was kept at 
less than 26 Gy and the heart V
30
 was less than or equal to 
45%. The maximum dose to the spinal cord was kept at less 
than 45 Gy. Liver constraints were: mean dose to the liver was 
less than 30 Gy and the liver V
30
 was less than or equal to 
40%. Finally, the dose to at least two thirds of the contralateral 
kidney was kept below 30 Gy. Interval histories and physi-
cal examinations were done weekly during treatment, after 
treatment events, and at each follow-up visit. CT imaging was 
obtained every 3 months for 2 years after treatment and yearly, 
thereafter.
IMRT Toxicity Assessment
Treatment-related toxicity was assessed weekly during 
radiation therapy, at 4 to 6 weeks after treatment, and then 
every 3 months thereafter. Toxicity was scored according 
to the Common Terminology Toxicity Criteria for Adverse 
Events version 4.0 and focused on esophageal, pulmonary, 
and cardiac toxicity.
Patterns of Failure
Patterns of failure were characterized in all patients who 
experienced disease recurrence. Treatment failure within the 
ipsilateral hemithorax was considered LR, and all other sites 
of failure were considered DM. For patients who experienced 
LR, archived radiation treatment plans were obtained and 
fused with the image that revealed the recurrence to estab-
lish whether the failure was in-field, marginal, or out-of-field. 
Marginal failures were those in which the recurrence lay par-
tially within and partially outside the isodose line representing 
the prescribed dose.
Statistical Considerations
Data were analyzed with Stata/SE 11.1 (StataCorp 
LP, College Station, TX). Actuarial rates of LR-free survival 
(LRFS), distant metastasis-free survival (DMFS), and over-
all survival (OS) were estimated by using the Kaplan–Meier 
method and compared with log-rank tests. Cox proportional 
hazards models were developed to identify associations 
between patient- and disease-related characteristics and the 
survival endpoints. Significance was determined using α = 
0.05, and variables found to be significant in univariate analy-
sis were then tested in multivariate analysis. Survival was cal-
culated from the date of surgery.
RESULTS
The median follow-up time for all 86 patients receiving 
EPP+IMRT was 10.2 months (range, <1–99.3 months), and 
the median follow-up time for all patients alive at the time 
of analysis was 13.9 months (range, 2.7–99.3 months). The 
median interval between surgery and IMRT was 2.4 months 
(range, 1.3–7.0 months).
Toxicity
Toxic effects secondary to IMRT are shown in Table 3. 
Almost all patients experienced gastrointestinal symptoms 
of grade 2 or more, primarily nausea, esophagitis, or both. 
Toxicity rates of grade 3 or higher were as follows: skin, 
17.4% (n = 15); gastrointestinal (e.g., esophagitis/nausea), 
16.3% (n = 14); heart, 2.3% (n = 2); and lung, 11.6% (n = 
10). Five patients experienced grade 5 toxicity, which were 
all pulmonary (3 radiation pneumonitis and 2 bronchopleural 
fistulae). Of the two patients who experienced cardiac toxicity 
of grade 3 or more, one had a pericardial effusion (grade 3), 
and the other developed severe cardiomyopathy with mark-
edly reduced ejection fraction (grade 4). Other grade 3 toxici-
ties included grade 3 dyspnea 2 to 6 months after completing 
IMRT (n = 2) and a seroma, possibly caused by radiation-
related chest wall disruption, requiring surgery. Patients who 
received induction chemotherapy did not experience higher 
rates of severe toxicity (p > 0.05), though the small number of 
such patients (n = 20) precluded full statistical analysis.
Survival and Patterns of Failure
At 1 year, OS rates were 54%, LRFS 88%, and DMFS 
71%; corresponding rates at 2 years were OS 32%, LRFS 55%, 
and DMFS 40%, and at 3 years were OS 22%, LRFS 54%, and 
TABLE 2.  Toxicity because of Extrapleural Pneumonectomy 
(N = 136)
Toxicity n (%)
Pulmonary
 Pneumonia 15 (11)
 Acute respiratory distress syndrome 4 (2.9)
Cardiovascular
 Atrial arrhythmias 59 (44)
 Myocardial infarction 3 (2.2)
 Ventricular arrhythmias 3 (2.2)
 Deep vein thrombosis 4 (2.9)
 Pulmonary embolism 3 (2.2)
Neurologic
 Cerebrovascular accident 2 (1.5)
 Exsanguination (intraoperative) 1 (0.7)
 Bleeding requiring reoperation 9 (6.6)
 Pleural space infection 2 (1.5)
 Bronchopleural fistula 4 (2.9)
 Recurrent laryngeal nerve paralysis 4 (2.9)
 Chylothorax 1 (0.7)
 Patch dehiscence 1 (0.7)
Other
 Empyema 9 (6.6)
 Sepsis 11 (8.1)
 Shock 2 (1.5)
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DMFS 21% (Fig. 1). Fourteen patients (16%) experienced LR 
and 51 patients (59%) had DM. Only two patients experienced 
LR alone; the other 12 patients had both LR and DM. Sites of 
DM were as follows: contralateral hemithorax, 41% (n = 35); 
abdomen and pelvis, including liver, 28% (n = 24); and bones, 
7% (n = 6). Some patients experienced recurrence at more than 
one distant site. Of the 14 patients who experienced LR, eight 
had multiple recurrences within the high-dose region, five 
patients had recurrences on the margin of a hemithoracic field 
(in a subcarinal lymph node, an ipsilateral subpectoral lymph 
node, a retrosternal mass, within a solitary pleural mass in 
the ipsilateral hemithorax, and in multiple mediastinal lymph 
nodes near the margin of the radiation field), and one patient 
had a recurrence in the ipsilateral supraclavicular region. 
Recurrence patterns for two patients, who experienced LR, 
one in a cold spot within the radiation field and the other in 
both a high-dose region and near the margin of the field, are 
shown in Figure 2.
In Figure 3, we have depicted a comparison of those 
patients who completed IMRT after EPP (median OS 14.7 
months) versus those patients who received EPP alone (median 
OS 4.5 months), both with respect to OS and disease-free sur-
vival. It is evident that survival outcomes are substantially 
improved with combined-modality therapy, primarily because 
inherent selection criteria for IMRT after EPP are factors that 
would affect these survival endpoints, such as poor perfor-
mance status, early treatment failure, and death (with only 
5 patients foregoing IMRT strictly because of patient refusal).
Factors Predicting Survival
Multivariate analysis indicated that the following fac-
tors were predictive of worse DMFS and OS in those patients 
receiving EPP+IMRT: nonepithelioid histology, higher nodal 
status, and lower pretreatment forced expiratory volume in 
1 second tested as a continuous variable (Table 4). Higher haz-
ard ratios in this table indicate an increased risk of an event 
(e.g., DM or death, respectively). No variables were found 
to be associated with LRFS. Grouping patients according to 
nodal status and histology also produced subgroups with dis-
tinct prognoses in terms of DM (Fig. 3A) and OS (Fig. 3B). 
Chemotherapy was not associated with any survival outcomes 
(p > 0.05).
DISCUSSION
Apart from Surveillance, Epidemiology, and End 
Results analyses, the current study represents the largest 
known series with complete clinical information for evaluating 
survival outcomes after EPP followed by IMRT for MPM. Our 
pertinent findings can be summarized as follows. First, a sig-
nificant number of patients (50, or 37%) who underwent EPP 
with planned adjuvant radiation did not receive IMRT because 
of poor performance status, postoperative complications, or 
the early development of DM. In addition, some patients did 
not receive postoperative radiation therapy for several months 
after treatment, because of either the administration of che-
motherapy or recovery from surgery, thereby questioning the 
adjuvant nature of this approach. Second, the predominant 
pattern of failure after this combined-modality approach was 
DM, and among those patients who experienced LR, most had 
treatment failures at multiple sites within the high-dose radia-
tion region, suggesting that radiation doses currently being 
used for this purpose do not control disease in at least some of 
these patients. Third, although this aggressive approach could 
produce significant toxicity (primarily gastrointestinal and 
dermatologic effects that required rigorous monitoring and 
care), the incidence of cardiopulmonary toxicity of grade 3 
or lesser was much lower (14%). Nevertheless, patients con-
sidering this treatment should be informed that even when 
FIGURE 1.  Kaplan–Meier survival curves for patients  
treated with extrapleural pneumonectomy followed by 
intensity-modulated radiation therapy for malignant pleural 
mesothelioma. A, Locoregional–progression-free survival;  
(B), distant metastasis–free survival; (C), overall survival.
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stringent dosimetric constraints are used, this approach car-
ries a low, although nonnegligible, risk (approximately 6%) 
of potentially fatal complications. Finally, histologic type and 
nodal status were the two primary disease factors that influ-
enced survival outcomes—further evidence that this aggres-
sive approach should be reserved mainly for patients with 
epithelioid tumors and negative mediastinal lymph nodes.
We previously reported outcomes and patterns of failure 
among 100 patients treated with EPP with or without adjuvant 
IMRT.5 In that study, for the 61 patients who underwent IMRT 
from 1999 to 2005, median OS was 14.2 months, 3-year OS 
was 20%, and eight patients (13%) had LR. The current analy-
sis, with a greatly expanded number of patients and with the 
increased use of positron emission tomography scan to evalu-
ate recurrence and patterns of failure in the recent cohort, cor-
roborated our previous finding of high rates of local control 
while closely evaluating the benefit of IMRT. Indeed, results 
from the current study compare favorably with those in other 
published studies of radiation after EPP. In one such study, 
among 13 patients treated with IMRT at Duke University, six 
(46%) had local failure.11 In another study at Memorial Sloan 
Kettering Cancer Center, a matched photon and electron 
(MPE) technique was used to deliver 54 Gy of hemithoracic 
radiation after EPP to a series of 61 patients.4 Although the 
median OS time in that study was 17 months, the median OS 
for the subset of patients most analogous to those in the cur-
rent study with stage III or IV disease, was just 10 months.3
Use of IMRT to deliver hemithoracic RT after EPP has 
been linked with high rates of fatal pneumonitis.12 Another 
risk factor for the development of severe pulmonary events has 
been the use of intraoperative cisplatin.13 However, since these 
studies were published, several others have demonstrated that 
FIGURE 2.  Fused PET or CT scans and radiation isodose curves (left) and diagnostic PET scans (right) of treatment failures in 
two different patients after extrapleural pneumonectomy followed by intensity-modulated radiation therapy for malignant  
pleural mesothelioma. A, Arrows indicate failure within a cold spot where the isodose lines curved inward along the chest wall 
and thus compromised target coverage in this portion of the radiation field. B, Recurrence in high-dose region and within  
subcutaneous tissues adjacent to the surgical scar. CT, computed tomography; PET, positron emission tomography.
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IMRT can provide both dosimetric superiority and good clini-
cal outcomes when appropriate dose constraints are used.14 
For example, in one analysis of 78 patients treated with MPM, 
67% of isolated local failures were in areas of dose inhomo-
geneity that would have had better coverage with IMRT.15 
Other studies from M.D. Anderson Cancer Center5 and other 
institutions6,7 have shown low rates of high-grade pneumonitis 
(5% in this study) and median survival times of 16 months or 
more with the use of IMRT. With the increasing adoption of 
IMRT and the growing acceptance that the mean dose to the 
ipsilateral lung should not exceed 8.0 Gy, the rates of adverse 
clinical consequences of the low-dose bath created by IMRT 
have been sharply reduced. Use of newer technologies such 
as volumetric-modulated arc therapy may also reduce patient 
treatment times while offering target volume coverage similar 
to IMRT with reduced contralateral lung doses.16
Our finding that IMRT after EPP led to a low rate of LR 
(16%), defined as recurrence in the ipsilateral hemithorax, is 
encouraging. Indeed, we found that OS thus correlated much 
more directly with time to DM, which led to a median OS 
time of 14.7 months. These findings are consistent with prior 
phase II studies examining the efficacy of trimodality therapy, 
in which OS times in excess of 20 months have been con-
sistently achieved.17 In one such analysis, patients in a phase 
II trial of neoadjuvant cisplatin and pemetrexed followed by 
EPP and IMRT/MPE had a median OS time of 29.1 months.7 
In another series, patients with N0 disease who successfully 
completed trimodality therapy at Princess Margaret Hospital 
had median OS times as long as 59 months.6 Achieving OS for 
longer than 5 years has proven to be much more difficult, and 
will likely necessitate the development of improved systemic 
regimens. Over the past decade, the addition of antifolates to 
platinum regimens has been shown to improve OS rates in 
several trials.18 With the recognition that MPMs often express 
activated Src kinase, prospective trials of dasatinib are also 
being undertaken in potentially resectable cases.19 Further 
results from studies such as these are eagerly anticipated.
Finally, consistent with prior reports from our institu-
tion and others,5,20,21 we found that patients with sarcomatoid 
or biphasic histology and mediastinal nodal involvement had 
substantially reduced survival outcomes with this aggressive 
technique. It is important to emphasize that largely based on 
findings over the past decade, which have shown, even with 
modern surgical and radiation techniques poor prognosis 
in patients who have these disease characteristics, the prac-
tice patterns at our institution have changed over time. The 
TABLE 3.  Toxicity in Patients Treated with Extrapleural 
Pneumonectomy Plus Hemithoracic Intensity-Modulated 
Radiation Therapy (n = 86)
Toxicity Type and Grade No. of Patients
Skin
 0 2
 1 59
 2 10
 3 15
Lung
 0 or 1 74
 2 3
 3 4
 4 1
 5 5
Heart
 0 80
 1 0
 2 4
 3 1
 4 1
Gastrointestinal
 0 6
 1 0
 2 66
 3 14
FIGURE 3.  Comparison of EPP alone with EPP + IMRT with regards to, (A), overall survival, and (B), disease-free survival. 
EPP, extrapleural pneumonectomy; IMRT, intensity-modulated radiation therapy.
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standard practice at our institution for high-risk patients is 
currently as follows. For patients with sarcomatoid disease, no 
surgery is recommended. Patients with known biphasic histol-
ogy or N2 stage are offered either lung-sparing surgery or no 
surgery, but an EPP is not currently recommended.
In addition to the weaknesses inherent in any retrospec-
tive study, the current analysis had several limitations. First, 
our patterns-of-failure analysis was limited by the lack of his-
tologic confirmation of recurrence in some cases, which would 
be available in a controlled prospective analysis. In these 
instances, the assessment of failure was made on the basis of 
the clinical and imaging data available in the medical record. 
Second, small patient numbers precluded full analysis of the 
effect of chemotherapy (e.g., the specific regimen, number of 
cycles, or timing) with regard to patterns of failure and survival 
outcomes. Third, as alluded to above, it is important to stress 
that recent trials of multimodality therapy involving lung-spar-
ing procedures have been published that demonstrate similar 
improved outcomes with these techniques when compared 
with EPP.1,22–24 Therefore, there remains no consensus as to the 
optimal approach in this setting, and lung-sparing techniques 
such as pleurectomy or decortication should be strongly con-
sidered, particularly in patients who are borderline candidates 
for EPP. Finally, although we have included a comparison of 
OS and DFS outcomes in patients who received EPP + IMRT 
versus EPP alone as mentioned above, this retrospective com-
parison is subject to substantial bias inherent in the use of a 
comparison group that received EPP alone because of underly-
ing factors that portend a worse prognosis. Indeed, we found in 
the current study that the vast majority of patients who did not 
undergo combined-modality treatment could not do so because 
of recurrence, toxicity, or poor performance status that ren-
dered postoperative radiation unfeasible. In other words, our 
approach in all patients who undergo EPP is an intention to 
treat with IMRT as well, with unanticipated early recurrences, 
postoperative complications, or declines in performance status 
precluding treatment with postoperative radiation.
CONCLUSIONS
Although lung-sparing surgery has emerged as a viable 
approach for patients with MPM, our results demonstrate that 
definitive EPP followed by IMRT for MPM produces high 
rates of locoregional control. While the rates of dermatitis and 
gastrointestinal symptoms were significant, the incidence of 
high-grade cardiopulmonary toxicity was low (although non-
negligible) when stringent dosimetric constraints were used. 
Technical advances may eventually permit better local control 
with less toxicity. However, even patients in whom locore-
gional control is achieved are at risk of developing DM, such 
that similar survival outcomes have been shown in trials using 
chemotherapy alone.25 Thus, further trials of systemic agents, 
including targeted therapies, are indicated.
FIGURE 4.  Kaplan–Meier curves illustrating (A), distant 
metastasis and (B), overall survival according to nodal status 
and histologic subtype in patients treated with extrapleural 
pneumonectomy plus intensity-modulated radiation therapy.
TABLE 4. Cox Proportional Hazard Models for Overall, Locoregional, Recurrence-Free, and Distant Metastasis–Free Survival 
 
Overall Survival
Locoregional Recurrence-Free 
Survival Distant Metastasis-Free Survival
HR [95% CI] p HR [95% CI] p HR [95% CI] p
Nonepithelioid histology  3.64 [1.47–5.70] <0.001 — — 3.46 [1.70–7.04] 0.001
N Status (N0–N1 vs. N2) 2.05 [1.14–3.69] 0.016 — — 1.95 [1.08–3.54] 0.028
Higher pretreatment FEV1 0.11 [0.01–0.95] 0.045 — — 0.10 [0.01–0.88] 0.038
Hazard ratios represent the risk of death, locoregional recurrence, and distant metastasis.
hr, hazard ratio; CI, confidence interval; FEV1, forced expiratory volume in 1 second.
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